Xtant Medical Holdings, Inc.
XTNT · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -2.86 | 0.13 | -0.18 |
| FCF Yield | 0.88% | 0.13% | -0.01% | -4.18% |
| EV / EBITDA | 18.54 | 45.27 | -105.00 | -44.86 |
| Quality | ||||
| ROIC | 5.04% | 0.33% | -2.42% | -4.68% |
| Gross Margin | 68.58% | 61.52% | 50.85% | 58.37% |
| Cash Conversion Ratio | 3.53 | 0.36 | 22.03 | -0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.26% | 23.45% | 24.78% | 26.47% |
| Free Cash Flow Growth | 945.98% | 1,342.86% | 99.82% | 32.38% |
| Safety | ||||
| Net Debt / EBITDA | 1.32 | 13.69 | -33.58 | -10.91 |
| Interest Coverage | 4.61 | 1.02 | -1.66 | -3.15 |
| Efficiency | ||||
| Inventory Turnover | 0.28 | 0.33 | 0.40 | 0.28 |
| Cash Conversion Cycle | 334.70 | 289.49 | 237.48 | 326.11 |